| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/25 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DNA-binding protein inhibitor ID-1, Class B basic helix-loop-helix protein 24, bHLHb24, Inhibitor of DNA binding 1, Inhibitor of differentiation 1, ID1, BHLHB24, ID |
| Entrez GeneID | 3397 |
| WB Predicted band size | 16.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This ID1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 66-93 amino acids of human ID1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于ID1抗体的参考文献示例(文献信息为虚拟概括，仅供示例参考)：
1. **文献名称**：*ID1 promotes tumor metastasis through activation of EMT in breast cancer*
**作者**：Smith A, et al.
**摘要**：本研究利用ID1特异性抗体进行免疫组化和Western blot分析，发现ID1蛋白通过上调Snail和Twist表达诱导上皮-间质转化(EMT)，促进乳腺癌细胞侵袭和转移。
2. **文献名称**：*ID1 maintains self-renewal of hematopoietic stem cells via Wnt/β-catenin signaling*
**作者**：Chen L, et al.
**摘要**：通过ID1抗体敲低实验及流式细胞术，证实ID1通过激活Wnt/β-catenin通路维持造血干细胞的干性，其缺失导致干细胞分化异常。
3. **文献名称**：*ID1 as a prognostic biomarker in colorectal cancer: An immunohistochemical study*
**作者**：Wang X, et al.
**摘要**：基于ID1抗体的免疫组织化学分析显示，ID1高表达与结直肠癌患者总生存期缩短显著相关，提示其可作为独立预后标志物。
4. **文献名称**：*Targeting ID1 inhibits angiogenesis in glioblastoma*
**作者**：Park J, et al.
**摘要**：通过ID1中和抗体阻断实验，发现ID1通过调控VEGF信号促进胶质母细胞瘤血管生成，抗体干预可显著抑制肿瘤血管形成。
(注：以上文献为示例性内容，实际文献需通过PubMed、Web of Science等数据库检索确认。)
The ID1 (Inhibitor of DNA Binding 1) antibody is a research tool used to detect and study the ID1 protein, a helix-loop-helix (HLH) transcriptional regulator lacking a DNA-binding domain. ID1 functions by dimerizing with basic HLH transcription factors (e.g., E proteins), inhibiting their ability to bind DNA and regulate target genes involved in cell differentiation, proliferation, and apoptosis. Initially identified in early embryonic development, ID1 is critical in maintaining stem cell pluripotency and tissue regeneration. However, its dysregulation is linked to pathological conditions, particularly cancer. Overexpression of ID1 is observed in aggressive tumors (e.g., breast, prostate, glioblastoma) and correlates with poor prognosis, promoting angiogenesis, metastasis, and therapy resistance.
ID1 antibodies enable researchers to investigate these mechanisms via techniques like Western blotting, immunohistochemistry, and flow cytometry. Commercial ID1 antibodies are typically raised against specific epitopes (e.g., human ID1 N-terminal peptides) and validated for cross-reactivity in multiple species (human, mouse, rat). However, variability in antibody specificity and batch consistency remains a challenge, necessitating careful validation. These reagents are pivotal in exploring ID1's role in developmental biology, oncology, and potential therapeutic targeting. Major suppliers include Santa Cruz Biotechnology, Abcam, and R&D Systems, offering monoclonal and polyclonal formats for diverse experimental applications.
×
